232 related articles for article (PubMed ID: 18995897)
1. Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.
Konuma T; Ooi J; Takahashi S; Tomonari A; Tsukada N; Kato S; Sato A; Monma F; Kasahara S; Uchimaru K; Iseki T; Tojo A; Asano S
Leuk Res; 2009 Jun; 33(6):840-2. PubMed ID: 18995897
[TBL] [Abstract][Full Text] [Related]
2. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
3. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Claviez A; Klingebiel T; Beyer J; Nürnberger W; Ehninger G; Suttorp M; Dreger P; Dörffel W; Schmitz N
Ann Hematol; 2004 Apr; 83(4):237-41. PubMed ID: 14625790
[TBL] [Abstract][Full Text] [Related]
5. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
[TBL] [Abstract][Full Text] [Related]
7. Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
Huugen D; Bos GM; Jansen M; Lalisang R; Jansen R; Wagstaff J; Schouten HC
Neth J Med; 2002 May; 60(4):170-3. PubMed ID: 12164395
[TBL] [Abstract][Full Text] [Related]
8. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM; Segeren CM; Verdonck LF; van der Holt B; Raymakers R; van Oers MH; Barge RM; Schouten HC; Westveer PH; Steijaert MM; Cornelissen JJ; Sonneveld P;
J Clin Oncol; 2003 May; 21(9):1728-33. PubMed ID: 12721248
[TBL] [Abstract][Full Text] [Related]
9. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
12. Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.
Ishikawa J; Maeda T; Kashiwagi H; Yoshida H; Takahashi I; Kawamoto SI; Yamada M; Kato H; Nishiura T; Tomiyama Y; Matsuzawa Y
Bone Marrow Transplant; 2003 Jun; 31(11):1057-9. PubMed ID: 12774060
[TBL] [Abstract][Full Text] [Related]
13. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.
Ivanov V; Faucher C; Mohty M; Bilger K; Ladaique P; Sainty D; Arnoulet C; Chabannon C; Vey N; Camerlo J; Bouabdallah R; Viens P; Maraninchi D; Bardou VJ; Esterni B; Blaise D
Bone Marrow Transplant; 2005 Nov; 36(10):901-6. PubMed ID: 16151421
[TBL] [Abstract][Full Text] [Related]
14. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Christopoulos P; Schmoor C; Waterhouse M; Marks R; Wäsch R; Bertz H; Finke J
Bone Marrow Transplant; 2013 Jul; 48(7):901-7. PubMed ID: 23376820
[TBL] [Abstract][Full Text] [Related]
16. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
17. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
[TBL] [Abstract][Full Text] [Related]
18. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of the outcome after second or subsequent allogeneic transplantation.
Kedmi M; Resnick IB; Dray L; Aker M; Samuel S; Gesundheit B; Slavin S; Or R; Shapira MY
Biol Blood Marrow Transplant; 2009 Apr; 15(4):483-9. PubMed ID: 19285636
[TBL] [Abstract][Full Text] [Related]
20. Second allogeneic hematopoietic SCT for relapsed ALL in children.
Kato M; Horikoshi Y; Okamoto Y; Takahashi Y; Hasegawa D; Koh K; Takita J; Inoue M; Kigasawa H; Ogawa A; Sasahara Y; Kawa K; Yabe H; Sakamaki H; Suzuki R; Kato K
Bone Marrow Transplant; 2012 Oct; 47(10):1307-11. PubMed ID: 22367344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
